ZYME FDA calendar & decision history Zymeworks Inc. · 1 upcoming · 0 past FDA decisions
Upcoming FDA catalysts ZYME · Aug 25, 2026 Ziihera (zanidatamab-hrii) - (HERIZON-GEA-01) — First-line HER2-positive gastroesophageal adenocarcinoma (GEA) See the full 2026 PDUFA calendar → This page aggregates ZYME's FDA catalysts from pdufa.bio's own calendar and decision archive. Each item links to its source page. Facts and dates only; verify against primary FDA / SEC / company filings.
Not affiliated with or endorsed by the FDA. pdufa.bio is an independent service; "FDA", "PDUFA", and all company, drug, and ticker names are used descriptively and remain the property of their owners. Informational and educational only — not investment advice. Data and historical statistics only; no trade recommendations and no individual-drug approval probabilities. Verify every date and outcome against primary FDA / SEC / company filings. © 2026 pdufa.bio